Sign in
Active, not recruitingNo phase

Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial

Key facts

Who runs it
University of Pennsylvania
Where
Ann Arbor and Philadelphia, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
300 people, planned
Started
20 Dec 2020
Expected to end
31 Dec 2027
Type of study
Observational
Treatments tested
  • No intervention. This is an observational study.
Record updated
6 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Enrolled in BOOST-3 (this is an ancillary study to the BOOST-3 trial)
  • BOOST-3 participant is enrolled at a BioBOOST site
  • Able to maintain initial blood sample within 24 hours of injury
  • Provide proxy informed consent

Who cannot take part

  • Age less than 18 years
  • Profoundly anemic (subjects who are profoundly anemic require blood transfusion)

Where in United States

  • University of MichiganAnn Arbor, United States
  • Penn Presbyterian Medical CenterPhiladelphia, United States

About the trial

What the trial wants to find out

BioBOOST is a multicenter, observational study of the effect of derangements in brain physiologic parameters on brain injury biomarker levels in patients with severe traumatic brain injury.

The group in the trial

  • Severe traumatic brain injury (TBI)

    This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.

    Treatment: No intervention. This is an observational study.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial (BioBOOST)
Record updated
6 May 2026